Pfizer Spins Off Esperion While Retaining Former Subsidiary’s Top Compounds
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer retains undisclosed stake in Esperion, which will focus on small-molecule dyslipidemia candidate.
You may also be interested in...
Esperion Expects Phase IIb Data By Year-End On Cholesterol Candidate
The recently public company completed Phase IIa studies for lead candidate ETC-1002 and intends to complete a pair of Phase IIb studies before year-end.
Financings Of The Fortnight: Spurred By U.S. JOBS Act, Biotech IPOs Flowing Steadily Now
Plus the latest financing news from Denmark’s Symphogen, ScioDerm, Esperion Therapeutics and Intrexon.
Aiming For Non-Statin Cholesterol Drug Market, Esperion Takes $33M
Spun out from Pfizer five years ago, the Ann Arbor, Mich., company hopes its Phase II candidate can capture a share of the market for high-cholesterol drugs prescribed to statin-intolerant patients.